Socio-Economic Rights Project (SERP)
Permanent URI for this collection
The Socio-Economic Rights Project, which focuses on the realization of the socio-economic rights of groups and communities living in poverty.
Browse
Browsing by Subject "Access to medicines"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
Item Compulsory licensing and access to medicines in post Doha era: What hope for Africa?(Netherlands International Law Review, 2008) Ebenezer, DurojayeThe Trade Related Aspects of Intellectual Property Rights (TRIPS) Agreement of 1994, an outcome of the Uruguay Round negotiations, radically altered the role of international trade law in promoting and enforcing intellectual property protection around the globe. This important, yet controversial, international agreement requires members of the World Trade Organization (WTO) to implement strong intellectual property protections in their domestic law. Indeed the emergence of the TRIPS Agreement at the end of deliberations in Marrakesh has been described as a major tactical victory for rich countries and pharmaceutical companies. Prior to 1994, countries of the world were not obligated to grant patent rights for pharmaceutical products, but with the signing of the TRIPS Agreement this changed. Along with this change, patent protection for pharmaceuticals, and the impact such patent protection is likely to have on access to medicines for the world’s poor, have become a major source of conflict between rich and poor nations.Item Revisiting the Trips Regime: Rwanda-Canadian ARV Drug Deal Tests the WTO General Council Decision(African Journal of International and Comparative Law, 2009) Rebecca, AmolloOn 17 July 2007, the world was awakened to Rwanda's notification of the World Trade Organisation's (WTO) Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS) that it plans to import the HIV-drug TriAvir from Canada's giant pharmaceuticals company, Apotex. Two months later, Canada issued a compulsory licence allowing Apotex to use nine patented inventions for manufacturing and exporting TriAvir to Rwanda. On 4 October 2007, Canada notified the Council for TRIPS of the compulsory licence. In September 2008, Apotex said it will ship seven million antiretroviral pills to Rwanda to treat 21,000 patients. Against this backdrop, this article uses the Rwandan-Canadian drug deal to examine the utility of the WTO General Council Decision in making ARV drugs more accessible to Low and Middle Income Countries so far. In doing so, the article's analyses rely on the regime of the Canadian Access to Medicines Regime which was enacted after the WTO Decision. The author discusses some of the issues arising from the deal in light of the effectiveness of the General Council Decision in solving the problem of access to antiretroviral drugs within the right to health and HIV/AIDS context. The article also raises questions relating to the willingness of developing countries to take benefit of the TRIPS flexibilities and the obligation of developed countries to ensure that the flexibilities become a reality.